A ultra-stable point of care nanozyme-based kit for cTnI detection in human serum

Home discovery of myocardial infarction can significantly improve the rate of treatment. Cardiac troponin I (cTnI), as a biochemical marker that has been introduced into clinical diagnosis and treatment guidelines, can effectively predict the occurrence of myocardial infarction. We constructed highly stable nanozyme based on Fe₃O₄ nanoparticles and prepared rapid detection reagents for myocardial infarction by modifying anti-cTnI antibodies. The results showed that the nanozyme with an average particle size of 200 nm had peroxidase activity and could effectively catalyze 3,3', 5,5'-tetramethylbenzidine (TMB). With a sensitivity of up to 1.5 ng/mL, the kit showed superior performance than commercial colloidal gold assay kits, and could effectively detect cTnI in serum with an overall compliance rate of 92.1%. The study provides a new approach to home detection of heart attacks.